10-Q quarterly report · filed Oct 29, 2026

Penumbra Inc (PEN) Q3 2026 10-Q Quarterly Report

Short answer

Penumbra Inc (PEN) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $410M (up 15.6% year over year) with net income of $42M.

Q3 2026 key financials · XBRL

Revenue
$410M
+15.6% YoY · +5.2% QoQ
Net income
$42M
−7.8% YoY · +21.5% QoQ
Operating margin
12.4%
Gross margin
68.3%
EPS (diluted)
$1.07
−8.5% YoY · +21.6% QoQ

Source: XBRL data from the Penumbra Inc (PEN) Q3 2026 10-Q on SEC EDGAR. USD.

Penumbra Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $410.1M, up 15.6% YoY from $354.7M
  • Thrombectomy strongest segment, $279.2M, up 18.1%; embolization and access $131.0M, up 10.8%
  • Gross margin 68.3% vs 67.8%; operating margin 12.4% vs 13.8%; net margin 10.3% vs 12.9%
  • Cash $254.3M vs $186.9M at December 31, 2025; marketable investments $419.3M vs $357.9M
  • Nine-month operating cash flow $174.6M; capital expenditures $42.3M, including Costa Rica facility construction
  • Near-term outlook: merger expected early 2027; Costa Rica project cost increased approximately $31M; continued product, manufacturing and international investment

Risk Factors

  • No material changes or new risk factors since the December 31, 2025 Form 10-K
  • Carried-forward risks include regulatory approval and compliance requirements for medical devices
  • Carried-forward risks include product liability, recalls, and patient safety exposure
  • Carried-forward risks include competition and dependence on successful product innovation
  • Carried-forward risks include manufacturing, supply-chain, and component availability disruptions

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Penumbra Inc quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.